“Global CTC Market is anticipated to grow on account of growing chronic oncology disease cases and applications of CTC in biomarkers for drug discovery is anticipated to fuel the growth of global market”, says new Visiongain report

05 September 2019
Pharma

Visiongain has launched a new pharma report Circulating Tumor Cells (CTC) Market Report 2019-2029: By Technology (CTC Detection Methods, CTC Enrichment Methods), by Application (Epithelial-Mesenchymal Transition (EMT) Biomarkers Development, Cancer Cell Research Segment, Others), by End Users (Diagnostic Centers, Hospitals and Clinics Segment, Academic & Research Laboratories, Others).

Global CTC Market is anticipated to grow on account of growing chronic oncology disease cases and applications of CTC in biomarkers for drug discovery is anticipated to fuel the growth of global market. The global CTC market is anticipated to grow at a lucrative CAGR of 14.7% and anticipated to reach USD 26.82 Billion by 2029.

CTCs are a prevalent topic in cancer research since liquid biopsy can be used to monitor a patient's condition, which is a minimally invasive procedure with more sample accessibility in comparison to tissue biopsy. Over the past centuries, the CTC study covered a wide range of subjects, such as profiling, enumeration, and correlation between the amount of CTC and patient overall survival. It is vital to separate and enrich CTCs before performing a CTC assessment because CTCs are very prevalent in blood flow (0–10 CTCs/mL of blood sample). Among various solutions to divide CTCs, microfluidics provides numerous attractive advantages for CTC studies, such as continuing sample processing to reduce target cell loss and easy integration of multiple characteristics into a chip, enabling "do-everything-on - a-chip."

The significance of early diagnosis of cancer and better cancer therapy has been obvious for years, and worldwide study has been introduced into fresh possibilities in the care strategy of cancer patients using technological innovations. One of the primary fields of study involves the detection and separation of CTC owing to their vital role in early diagnosis and prognosis of cancer.

Currently, cancer-related diseases are one of the major health issues in the world, causing around eight million deaths each year, and it is anticipated that this amount will increase rapidly in the future. Therefore, research on cancer therapy and early diagnostic techniques is essential. Modern, innovative methods can carry out tasks that were previously impossible. The primary diagnostic and therapy methods for cancer patients are gradually moving from standard norms to customized techniques due to these advances.

North America holds majority of market share followed by Europe and will continue to dominate in the future as a result of a number of research projects in the region, coupled with funding for research institutes from the government. In addition, the market will continue to be driven by the existence of target population and increased R&D investment by important business organizations. Asia Pacific region is expected to experience the highest growth in terms of CAGR over the forecast period owing to growing presence of cancer cases in markets such as India and China. Additionally, unmet needs of patients and untapped nations in this region have been attracting investments by global players and this is expected to boost CTC market growth over the forecast period.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products in order to strengthen their position in the global single-cell genomics market. Companies are also expanding their R&D, distribution, and management facilities in order to expand their business and to hold a competitive edge in the market.

The comprehensive market report features companies such as AdnaGen AG, Advanced Cell Diagnostics, Apocell, Aviva Biosciences, Biocep Ltd., Biocept, Inc., Biofluidica, Canopus Biosciences, CellTraffix, Inc., CellTraffix, Inc., Clearbridge BioMedics, Creatv Microtech, Inc., Cynvenio Biosystems, Epic Biosciences, Fluxion Biosciences, Inc., GE Healthcare, Greiner Bio-one GmbH, F Hoffmann-La Roche Ltd, Ikonisys, Inc., Janssen Diagnostics, LungLife AI Inc., Menarini Silicon Biosystems, Menarini Silicon Biosystems, Miltenyi Biotech, Miltenyi Biotech, NanoString Technologies, Inc., Qiagen, SRI International, STEMCELL Technologies, Sysmex Corp., Thermo Fisher Scientific and Vitatex, Inc. among other prominent players.

Also the research study offers market estimation and forecast for the period ranging 2019–2029 for global markets such as North America, Latin America, Western Europe, Eastern Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Russia, Poland, India, Japan, China, Australia, ASEAN, GCC, South Africa and North Africa.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Human Microbiome Therapeutics market set to grow to $1.6bn” by 2025 says new Visiongain report

The market for microbiome therapeutics is expected to commence around mid-2020 with the launch of new products relating to dermatology and gastrointestinal disorders.

04 December 2019

Read

“Global Next-Generation Biologics market set to grow to $42bn by 2024” says new Visiongain report

Technological developments in the next-generation biologics market will be the result of clinical development of multiple platforms in the next-generation antibody, antibody fragment and ALP sectors.

04 December 2019

Read

“Global Liquid Biopsy market set to grow to $4.9bn by 2024” says new Visiongain report

The main drivers for the growth include technological advancements such as development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

04 December 2019

Read

“Global nucleic acid isolation and purification market is anticipated to reach USD 8.16 Billion by 2030”, says Visiongain

Nucleic acid separation and purification is one of modern science and technology’s most complex and critical accomplishments.

29 November 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever